Navigation Links
Justin Zamirowski Appointed as Chief Commercial Officer
Date:7/31/2020

Justin Zamirowski to lead upcoming launches of Better Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on Type 2 diabetes and associated comorbidities.

Justin brings over 20 years of diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ efforts in market development and commercial operations to prepare for the upcoming launch of BT-001, a prescription digital therapeutic delivering nutritional cognitive behavior therapy (nutritional CBT), a novel form of behavioral therapy. BT-001 is intended to help adult patients with type 2 diabetes, under the guidance of their physician, improve glycemic control by lowering HbA1c.

“I’m excited and humbled to be part of the Better team and for the opportunity to transform the system of care for the most common, costly and complex chronic diseases,” said Justin. “In clinical trials, Better’s digital therapeutics have demonstrated the ability to improve clinical outcomes in patients with even long-standing diabetes and comorbidities. By harnessing data generated through patient use and remote monitoring, we can create feedback mechanisms to providers that inform clinical decision-making and improve the overall quality of care.”

Most recently, Justin served as the life science practice lead for launch at Guidehouse (formerly Navigant Consulting), where he was responsible for providing commercial and launch leadership to pharmaceutical, biotech, and medical device companies. “Justin’s diverse experience launching regulated products across multiple systems of care, stakeholder groups, treatment settings and therapeutic areas, will help us build a commercial capability as innovative as our products,” said Kevin Appelbaum, CEO of Better Therapeutics.

Prior to Guidehouse, Justin held commercial leadership roles at Edge Therapeutics and Otsuka, where he launched products across cardiovascular, central nervous system, and oncology therapeutic areas. Justin received his B.S. in biology from Illinois Wesleyan University, and resides in the Princeton, NJ area.

About Better Therapeutics
Better Therapeutics is developing prescription digital therapeutics (PDTs) for the treatment of diabetes, heart disease, and other chronic conditions. Today, drugs are used to treat the effects of these diseases while leaving the behaviors that cause them in place. Better's PDTs treat and often reverse disease by changing behaviors using nutritional CBT, a novel form of digitally-delivered behavioral therapy. Better’s PDTs are clinically-validated, FDA-regulated software applications intended to be prescribed by physicians and reimbursed like traditional medicines.

Read the full story at https://www.prweb.com/releases/justin_zamirowski_appointed_as_chief_commercial_officer/prweb17294987.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis
2. Sue Behrens Appointed to Lead KGI Bioprocessing Programs
3. Timothy I. Still Appointed as President and CEO of Myoscience
4. Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB)
5. NJIT professor appointed to National Research Council
6. For disappointed sports fans, defeats increase consumption of fat and sugar
7. PETA International Science Consortium disappointed in denial of Dow appeal
8. Former FDA Branch Chief of Radiation Programs Joins NDA Partners as Expert Consultant
9. Crop Enhancement Expands Leadership Team with Chief Business and Technology Officers
10. BioLabs Names John R. Freeman, CPA, Chief Financial Officer
11. RG+A Strengthens Its Executive Team by Appointing New Chief Executive Officer and President/Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2020)... PHOENIX (PRWEB) , ... July 03, 2020 , ... ... is proud to earn outstanding recognition and multiple awards for not only the ... the ABM portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... software solutions for biopharmaceutical R&D, today announced that it has entered into ... full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy ...
(Date:6/23/2020)... ... 2020 , ... The field of quantitation of large molecules or proteins has ... area. However, the use of mass spectrometry in this field has gained a lot ... do you choose which approach to use (LBA or MS)?” In many cases, ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
(Date:7/7/2020)... ... 2020 , ... Bio-IT World has announced the winners of ... University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were ... outstanding examples of how technology innovations and strategic initiatives can be powerful forces ...
Breaking Biology Technology: